When GSK (LSE:GSK) demerged its consumer health arm as Haleon in July 2022, the logic was simple: free the pharmaceutical Business to be judged on its science rather than on toothpaste and painkillers. Four years on, specialty medicines, vaccines and a rebuilt oncology Franchise drive growth, and a new chief executive is reshaping the cost base.

The reinvention has three strands. First, a sales mix tilted towards higher-growth specialty products. Second, more aggressive deal-making, capped in June 2026 by the roughly $10.6bn agreed Takeover of US biotech Nuvalent, GSK's largest deal in more than a decade. Third, a new three-year "Accelerate Growth" programme intended to strip out costs and redirect money into R&D.

The question for investors is whether this is enough to carry GSK through the loss of exclusivity on dolutegravir, the backbone of its HIV business, between 2028 and 2030.

How the business makes money

GSK now reports three product groups. Specialty Medicines, which includes HIV (through its majority-owned ViiV Healthcare joint venture), oncology, respiratory Biologics such as Nucala and immunology, is the largest, generating £13.5bn of sales in 2025. Vaccines, led by the shingles jab Shingrix, the meningitis portfolio and the RSV Vaccine Arexvy, contributed £9.2bn. General Medicines, dominated by inhaled respiratory brands including Trelegy, delivered £10.0bn.

HIV alone accounted for £7.7bn of 2025 sales, which explains why the dolutegravir Patent cliff attracts so much attention. ViiV's ownership also changed on 31 March 2026: Pfizer's stake was bought out and Shionogi raised its economic interest to 21.7%, leaving GSK with 78.3%.

Recent performance

For the year to 31 December 2025, turnover rose 7% at constant exchange rates (CER) to £32.7bn. Specialty Medicines grew 17% and oncology 43%, while Vaccines managed 2% and General Medicines slipped 1%. Core operating profit climbed 11% at CER to £9.78bn and core Earnings Per Share rose 12% at CER to 172.0p. The full-year Dividend was 66p, and free Cash Flow reached £4.0bn.

Momentum carried into 2026. In the six months to 30 June 2026, turnover increased 5% at CER to £16.0bn, core operating profit rose 8% at CER to £5.45bn and core EPS grew 9% at CER to 97.1p. In the second quarter, Specialty Medicines sales rose 14%, oncology 17% and HIV 10%, while Arexvy more than doubled to £192m. The drag came from General Medicines, down 9%, with Trelegy falling 7% as US Medicare changes and pricing pressure bit.

Statutory numbers were far weaker. Second-quarter total operating profit fell 75% at CER, mainly because GSK wrote down £1.3bn on camlipixant, its chronic cough candidate, after late-stage trials showed limited efficacy.

Guidance for 2026 has been reaffirmed: turnover growth at the upper half of a 3% to 5% range, and core EPS growth at the lower half of 7% to 9%, the latter reflecting about £800m of interest charges that include the cost of financing Nuvalent. A 70p dividend is expected for the year, and a £2bn share buyback was completed in June 2026.

Strategy and catalysts

Luke Miels, formerly chief commercial officer, succeeded Emma Walmsley as chief executive at the start of 2026, following an announcement in September 2025. Accelerate Growth targets £1.9bn of annual savings by 2029, at an expected cost of £2.4bn, partly to protect margins through the dolutegravir expiry window.

Deal-making has picked up. In early 2026 GSK agreed to buy RAPT Therapeutics for about $2.3bn including fees, gaining a long-acting anti-IgE antibody being tested for food allergy, and 35Pharma for $950m, adding a pulmonary hypertension candidate. Nuvalent brings two late-stage lung cancer drugs: Jideytro, already approved by the US Food and Drug Administration, and neladalkib, with a US regulatory decision due in the second half of 2026.

The pipeline calendar is busy. GSK won five major US approvals in 2025, including Blenrep, the asthma biologic Exdensur and Nucala for COPD. Near-term events include further data on the hepatitis B drug bepirovirsen, which GSK says produced unprecedented functional cure rates in pivotal studies, and more than 20 planned phase III trial starts during 2026. Management remains confident of its outlook for more than £40bn of sales by 2031.

US policy is also clearer: an April 2026 agreement with the US government gives GSK relief from Section 232 pharmaceutical tariffs until January 2029, in return for pricing commitments already reflected in guidance.

Valuation talking points

GSK has long traded at a discount to many large pharmaceutical peers, reflecting worries about its HIV patent cliff and pipeline. Key talking points include:

  • The 70p expected 2026 dividend, up from 66p in 2025 and comfortably covered by core earnings.
  • Whether continued high-single-digit core EPS growth is achievable as net Debt rises; it stood at £15.1bn on 30 June 2026.
  • The persistent gap between core and statutory earnings, which widened sharply in 2026 because of impairments.

The bull case

  • Specialty Medicines and oncology are growing at double-digit rates, steadily diluting exposure to older respiratory products.
  • Nuvalent adds an approved lung cancer drug and a near-term launch candidate, strengthening a franchise that grew 43% in 2025.
  • Accelerate Growth should support margins through the 2028 to 2030 dolutegravir expiry period.
  • A rising dividend, a completed £2bn buyback and £2.8bn of free cash flow in the first half of 2026 underline cash generation.
  • Tariff relief to 2029 removes one major policy uncertainty.

The bear case

  • HIV remains a large share of sales, and the dolutegravir cliff could prove steeper than management expects.
  • The camlipixant failure shows that late-stage bets can still go wrong, and pipeline setbacks translate into large write-downs.
  • Trelegy and the wider General Medicines division are shrinking faster, hurt by US Medicare reform and pricing pressure.
  • Borrowing to fund acquisitions raises interest costs, which are already pushing core EPS growth to the lower half of guidance.
  • Vaccine growth has been modest, with Shingrix up only 3% at CER in the second quarter of 2026.

The bottom line

Four years after Haleon, GSK (LSE:GSK) is a more focused biopharma business, with growth coming from specialty medicines, oncology and a handful of promising launches, led by a chief executive willing to cut costs and spend heavily on acquisitions.

The next two years will test whether that reinvention can outrun the dolutegravir patent cliff. The Nuvalent integration, the bepirovirsen filing and delivery against the £40bn-plus 2031 ambition are the milestones investors will be watching most closely.